Boehringer Ingelheim USA Corporation

Express Scripts, part of Cigna's Evernorth, plans to add three biosimilars to its National Preferred Formulary, including Sandoz's Hyrimoz and Adalimumab-adaz, and Boehringer Ingelheim's Cyltezo. These FDA-approved biosimilars offer cost-effective, clinically effective alternatives to HUMIRA for inflammatory conditions, aiming to reduce drug spending and increase treatment access. This move reflects Cigna's strategy to generate cost savings and potentially boost pharmacy revenues, with pharmacy revenues contributing 71.2% to Cigna's 2022 revenues.

Quantro Therapeutics partners with Boehringer Ingelheim in a 3-year deal to develop cancer therapy inhibitors targeting transcription factors, utilizing Quantro's innovative drug discovery platform. This collaboration aims to overcome challenges in targeting transcription factors, advancing Boehringer Ingelheim's strategy for breakthrough cancer therapies.

The human microbiome, crucial for health, influences metabolic functions, immunity, and disease prevention. Dysbiosis can lead to disorders, but microbiome-based treatments show promise for over 25 conditions, including infectious and autoimmune diseases. Recent FDA approvals for treatments like Rebyota® and VOWST™ highlight advancements. Research and investment in microbiome therapeutics are growing, with significant contributions from small companies and increasing interest from Big Pharma and investors.

Risankizumab showed non-inferiority for clinical remission at week 24 and superiority for endoscopic remission at week 48 compared to ustekinumab in treating Crohn's disease. All secondary endpoints were statistically significant, with a consistent safety profile for risankizumab.

The Global Type 1 Diabetes - T1D Market Report 2024 provides insights into market size, CAGR, and industry statistics, segmented by type (Rapid Acting, Long Acting, Premix Insulin Analogs) and application (Children, Adults). It covers market dynamics, trends, opportunities, and competitive landscape, including key players like Novo Nordisk and Sanofi. The report offers regional and country-level analysis, with customizable segments and data available upon request.

The article highlights advancements in covalent drug discovery, focusing on inhibitors targeting KEAP1/NRF2, KRAS(G12C), WRN helicase, and other oncology targets. It discusses novel compounds like BBO-8520, RMC-9805, VVD-214, and PF-07817883, emphasizing their mechanisms, clinical trials, and potential in treating cancers and COVID-19. The piece also covers the evolution of covalent inhibitors beyond oncology, showcasing significant approvals and acquisitions.

Celltrion seeks FDA approval for its adalimumab biosimilar Yuflyma's interchangeability with Humira, aiming for a 2023 launch. Formycon reports positive phase 3 trial results for its ustekinumab biosimilar FYB202, comparable to Stelara in treating psoriasis, highlighting progress in biosimilar development.

QUANTRO Therapeutics achieves transcriptomic drug discovery breakthroughs, collaborates with IMP and Boehringer Ingelheim, secures Austrian research grant, and appoints Dr. Michael Bauer as CEO, advancing oncology treatments.

QUANTRO Therapeutics GmbH, with seed funding from Boehringer Ingelheim Venture Fund and Evotec, aims to discover novel therapeutics targeting disease-causing transcriptional programs, especially in cancer. Utilizing 'Transcriptional Fingerprinting' and innovative functional genetics, QUANTRO focuses on oncogenic transcription factors, previously challenging to target. Founded by Dr. Stefan Ameres and Dr. Johannes Zuber, the company leverages expertise in transcriptomics and functional genomics, supported by ERC grants. QUANTRO's approach promises to unlock new therapeutic interventions in cancer and other diseases.

QUANTRO Therapeutics, a new start-up, aims to revolutionize cancer drug screening by targeting cancer-associated transcription factors using advanced technologies like SLAMseq. Founded by scientists Stefan Ameres and Johannes Zuber, with support from IMP and IMBA, QUANTRO has secured investment from Boehringer Ingelheim Venture Fund and Evotec, and is based in Vienna's BioCenter.